Cervarix (Cervical Cancer) - Analysis and Forecasts to 2020

Date: October 1, 2011
Pages: 28
Price:
US$ 2,000.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C873FEC2C4AEN
Leaflet:

Download PDF Leaflet

Cervarix (Cervical Cancer) - Analysis and Forecasts to 2020
Cervarix (Cervical Cancer) - Analysis and Forecasts to 2020

Summary

GlobalData’s pharmaceuticals report, “Cervarix (Cervical Cancer) - Analysis and Forecasts to 2020” provides Cervarix sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2007-2020). The report also includes information on Cervical Cancer market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Summary
  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Cervarix including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Cervarix including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2007-2020 for Cervarix in the seven major markets

Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 INTRODUCTION

2.1 Cervical Cancer Vaccines Market
2.2 Epidemiology
2.3 Etiology
  2.3.1 HPV Infections
  2.3.2 Lack of Regular Papanicolaou (pap) Tests
  2.3.3 Smoking
  2.3.4 Sexual History
  2.3.5 Birth Control Pills
2.4 GlobalData Report Guidance

3 CERVICAL CANCER VACCINES: MARKET CHARACTERIZATION

3.1 Cervical Cancer Vaccines Market
3.2 Drivers and Challenges for the Cervical Cancer Market
  3.2.1 Drivers for Cervical Cancer Vaccine Market
  3.2.2 Challenges for Cervical Cancer Vaccines

4 CERVARIX

4.1 Introduction
4.2 Mechanism of Action
4.3 Clinical Studies
4.4 Approval History
4.5 Factors Affecting Sales of Cervarix
  4.5.1 High Efficacy
  4.5.2 High Cost Effectiveness
  4.5.3 Large Target Population
  4.5.4 Limited Competition
  4.5.5 Low Compliance
4.6 Vaccine Evaluation
  4.6.1 Efficacy
  4.6.2 Safety
  4.6.3 Dosing Convenience
4.7 Intensity of Competition
4.8 Sales forecast
  4.8.1 Target Population of Cervarix
  4.8.2 Dosing
  4.8.3 Market Penetration
  4.8.4 Annual Cost of Therapy
  4.8.5 Sales Projections of Cervarix

5 CERVICAL CANCER VACCINE MARKET: APPENDIX

5.1 Market Definitions
5.2 List of Abberiviations
5.3 Research Methodology
  5.3.1 Coverage
  5.3.2 Secondary Research
  5.3.3 Forecasting
  5.3.4 Population Approved to take Vaccine
  5.3.5 Net Penetration of Vaccine
  5.3.6 Net Annual Dosing
  5.3.7 Annual Cost of Therapy
  5.3.8 Primary Research
  5.3.9 Expert Panels
5.4 Contact Us
5.5 Disclaimer
5.6 Sources

LIST OF TABLES

Table 1: Cervical Cancer, Estimated Incidences and Mortality, 2010-2020
Table 2: Estimated Prevalence of HPV in 9-26 years women
Table 3: Cervarix History
Table 4: Cervarix Approval and Expiry
Table 5: Cervarix, Cervical Cancer, the US, EU-5 and Japan, Estimated Sales($m), 2007-2020
Table 6: Cervarix, Cervical Cancer, the US, Estimated Sales($m), 2009-2020
Table 7: Cervarix, Cervical Cancer, the UK, Estimated Sales($m), 2007-2020
Table 8: Cervarix, Cervical Cancer, France, Estimated Sales($m), 2007-2020
Table 9: Cervarix, Cervical Cancer, Germany, Estimated Sales($m), 2007-2020
Table 10: Cervarix, Cervical Cancer, Italy, Estimated Sales($m), 2007-2020
Table 11: Cervarix, Cervical Cancer, Spain, Estimated Sales($m), 2007-2020
Table 12: Cervarix, Cervical Cancer, Japan, Estimated Sales($m), 2009-2020

LIST OF FIGURES

Figure 1: Estimated Prevalence of HPV in Women Aged between 9-26 Years in the US,EU-5 and Japan, 2010-2020
Figure 2: Cervarix, Cervical Cancer, the US, EU-5 and Japan, Estimated Sales($m), 2007-2020
Figure 3: Distribution of Incidence and Mortality, Global, Top 26 Diagnosed Cancers,2010
Figure 4: Difference Between Percentage Distribution of Incidence and Mortality of Top 19 Cancers, 2008
Figure 5: Per Capita Cigarette Consumption, the US, 1976-2006
Figure 6: Target Population
Figure 7: Cervarix, Cervical Cancer, the US, EU-5 and Japan, Estimated Sales($m), 2007-2020
Figure 8:Cervarix, Cervical Cancer, the US, Estimated Sales($m), 2009-2020
Figure 9:Cervarix , Cervical Cancer, the UK, Estimated Sales($m), 2007-2020
Figure 10:Cervarix, Cervical Cancer, France, Estimated Sales($m), 2007-2020
Figure 11:Cervarix, Cervical Cancer, Germany, Estimated Sales($m), 2007-2020
Figure 12:Cervarix, Cervical Cancer, Italy, Estimated Sales($m), 2007-2020
Figure 13:Cervarix, Cervical Cancer, Spain, Estimated Sales($m), 2007-2020
Figure 14: Cervarix, Cervical Cancer, Japan, Estimated Sales($m), 2009-2020
Figure 15: GlobalData Methodology

Ask Your Question

Cervarix (Cervical Cancer) - Analysis and Forecasts to 2020
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: